Cited by 478Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Kastelein, John J.P., van der Steeg, Wim A., Holme, Ingar, Gaffney, Michael, Cater, Nilo B., Barter, Philip, Deedwania, Prakash, Olsson, Anders G., Boekholdt, S. Matthijs, Demicco, David A., Szarek, Michael, LaRosa, John C., Pedersen, Terje R., Grundy, Scott M.·2008·Circulation

DOI 10.1161/circulationaha.107.713438

Open this paper in CoChat — free account

Abstract

BACKGROUND: Low-density lipoprotein (LDL) cholesterol is the principal target of lipid-lowering therapy, but recent evidence has suggested more appropriate targets. We compared the relationships of on-treatment levels of LDL cholesterol, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B, as well as ratios of total/HDL cholesterol, LDL/HDL cholesterol, and apolipoprotein B/A-I, with the occurrence of cardiovascular events in patients receiving statin therapy. METHODS AND RESULTS: A post hoc analysis was performed that combined data from 2 prospective, randomized clinical trials in which 10,001 ("Treating to New Targets") and 8888 ("Incremental Decrease in End Points through Aggressive Lipid Lowering") patients with established coronary heart disease were assigned to usual-dose or high-dose statin treatment. In models with LDL cholesterol, non-HDL cholesterol and apolipoprotein B were positively associated with cardiovascular outcome, whereas a positive relationship with LDL cholesterol was lost. In a model that contained non-HDL cholesterol and apolipoprotein B, neither was significant owing to collinearity. Total/HDL cholesterol ratio and the apolipoprotein B/A-I ratio in particular were each more closely associated with outcome than any of the individual proatherogenic lipoprotein parameters. CONCLUSIONS: In patients receiving statin therapy, on-treatment levels of non-HDL cholesterol and apolipoprotein B were more closely associated with cardiovascular outcome than levels of LDL cholesterol. Inclusion of measurements of the antiatherogenic lipoprotein fraction further strengthened the relationships. These data support the use of non-HDL cholesterol or apolipoprotein B as novel treatment targets for statin therapy. Given the absence of interventions that have been proven to consistently reduce cardiovascular disease risk through raising plasma levels of HDL cholesterol or apolipoprotein A-I, it seems premature to consider the ratio variables as clinically useful.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.107.713438

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Untitled work
(1996) · Cited by 6,884
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citation
Global Burden of Cardiovascular Diseases
Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. S. (2001) · Circulation · doi:10.1161/hc4601.099487 · Cited by 3,014
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548

Flagged first, then by citations

Show all 45 references

Research works printed but not linked: 5

10.1161/circ.104.22.2746 · DOI
10.1161/circ.101.5.477 · DOI
10.1161/circ.105.10.1162 · DOI
10.1161/circ.60.2.312704 · DOI
10.1161/circ.89.3.8124825 · DOI

Sorted by citations

Items 301–400 of 478

Elevated ApoB/ApoA-Ι ratio is associated with poor outcome in acute ischemic stroke
Li, Z.-Z., Zhang, D., Song, Z., Cui, X., Liu, L., Ding, Y., Xue, J., Zhang, X., Ma, R., Zhu, X., et al. (2022) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2022.11.007 · Cited by 8
Niveles plasmáticos de apolipoproteínas en una población saludable de la Argentina: implicaciones en prevención cardiovascular
Siniawski, D. A., Masson, W. M., Bluro, I. M., Sorroche, P. B., Scordo, W., Krauss, J. G., & Cagide, A. M. (2025) · Revista Argentina de Cardiología · doi:10.7775/rac.v77i2.2158 · Cited by 6
Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy.
Mazanderani, A., Wise, S. J., & Tildesley, H. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.05.013 · Cited by 7
Clinical Insights From the Treating to New Targets Trial
Waters, D. D. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.01.001 · Cited by 8
Discordância entre Colesterol LDL e Não-HDL e Gravidade da Doença Arterial Coronária
Kurmuş, Ö., Erkan, A. F., Ekici, B., Aslan, T., & Eren, M. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20190091 · Cited by 10
To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa
Yang, I. T., Hemphill, L., Kim, J., Bibangambah, P., Sentongo, R. N., Kakuhire, B., Plutzky, J., Boum, Y., Tsai, A. C., Okello, S., et al. (2020) · Journal of Global Health · doi:10.7189/jogh.10.010407 · Cited by 11
Predictors of the intima‐media thickness of carotid artery in asymptomatic newly detected severe hypercholesterolemic patients
Vladimirova‐Kitova, L., Deneva, T., & Marinov, B. I. (2010) · Clinical Physiology and Functional Imaging · doi:10.1111/j.1475-097x.2010.00935.x · Cited by 8
Correction to: Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry
Shiiba, M., Zhang, B., Miura, S., Ike, A., Nose, D., Kuwano, T., Imaizumi, S., Sugihara, M., Iwata, A., Nishikawa, H., et al. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1123-7 · Cited by 8
Association between atherogenic indexes and erectile dysfunction: a cross-sectional analysis of the National Health and Nutrition Examination Survey 2001–2004
Guo, L., Nan, Y., & Yao, L. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04050-4 · Cited by 7
Association of HDL cholesterol with all-cause and cardiovascular mortality in primary hypercholesterolemia
Bea, A. M., González-Guerrero, A., Cenarro, A., Lamíquiz-Moneo, I., Climent, E., Jarauta, E., Gracia‐Rubio, I., Benaiges, D., Laclaustra, M., Tejedor, M. T., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118617 · Cited by 7
Consumption of Oxidized and Partially Hydrogenated Oils Differentially Induces Trans-Fatty Acids Incorporation in Rats' Heart and Dyslipidemia
Dhibi, M., Bhouri, A. M., Brahmi, F., Houas, Z., Chargui, I., Kharroubi, W., & Hammami, M. (2015) · Journal of the American College of Nutrition · doi:10.1080/07315724.2014.938183 · Cited by 7
Relationship between serum levels of fetuin-A with apo-A1, apo-B100, body composition and insulin resistance in patients with type 2 diabetes.
Shidfar, F., Zarrati, M., Khamseh, M. E., Haghighat, N., Rostami, A., & Zolfaghari, H. (2014) · PubMed Central · Cited by 7
Total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol as predictors of coronary artery calcification assessed by multidetector computed tomography coronary angiography.
Seaoud, E. A. M. E., Amin, M. I., & Abdelbasit, M. S. (2022) · PubMed Central · doi:10.48305/arya.v18i0.2306 · Cited by 8
Triglyceride enhances susceptibility to TNF-α-induced cell death in THP-1 cells
Lim, J., Kim, Y. S., Kim, S. H., Cho, Y., Lee, M. H., Jung, B. C., Jung, D., & Rhee, K.-J. (2013) · Genes & Genomics · doi:10.1007/s13258-013-0144-y · Cited by 7
Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study
IDRIS, I. R., Tate, H., Ahmad, A., & McCormack, T. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.06.001 · Cited by 7
Comparison of Evidence-Based Versus Non–Evidence-Based Pharmacotherapy on the Risk of Cardiovascular Hospitalization and All-Cause Mortality Among Patients With Established Cardiovascular Disease
Nichols, G. A., Wang, F., & Pedula, K. L. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.11.008 · Cited by 7
Non‐high‐density lipoprotein cholesterol as a cardiovascular risk screening tool in children
Miyazaki, A., Oguri, A., & Ichida, F. (2015) · Pediatrics International · doi:10.1111/ped.12891 · Cited by 7
Non-HDL as a Valid Surrogate Marker of Small Dense LDL in a Young Indian Population
Manocha, A., Bhargava, S., Jain, R., Kankra, M., Singla, P., & Chugh, P. (2018) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-018-0758-6 · Cited by 6
Discordance between non-HDL cholesterol and LDL cholesterol levels in patients with diabetes without previous cardiovascular events
IDRIS, I. R., & Al-Ubaidi, F. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.02.002 · Cited by 7
Clinical, Anthropometric and Biochemical Characteristics of Patients with or without Genetically Confirmed Familial Hypercholesterolemia
Lorenzo, A. D., da Silva, J. D. L., James, C. E., Pereira, A. C., & Moreira, A. S. B. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180005 · Cited by 7
Metabolic Syndrome
Grundy, S. M. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_3 · Cited by 7
The Year in Atherothrombosis
Sanz, J., Moreno, P., & Fuster, V. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.047 · Cited by 8
Analysis of the Correlation between Non-high Density Lipoprotein Cholesterol and Coronary Heart Disease in Elderly Chinese
Ke, D., Chen, Q., Wu, Q. F., Li, X., Wu, Z., Li, G., Deng, W., & Mo, X. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4988 · Cited by 6
A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG/HDL-C ratio only in young Chinese females
Song, Y., Gong, R. R., Zhang, Z., Li, Y. H., Xiao, L. Y., Zhou, X., & Fang, D. Z. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500065 · Cited by 6
Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients
Joshi, P. H., Miller, P. E., Martin, S. S., Jones, S. R., Massaro, J. M., D’Agostino, R. B., Kulkarni, K. R., Sponseller, C. A., & Toth, P. P. (2017) · AIDS · doi:10.1097/qad.0000000000001423 · Cited by 6
Prediction of future cardiovascular disease with an equation to estimate apolipoprotein B in patients with high cardiovascular risk: an analysis from the TNT and IDEAL study
Hwang, Y., Ahn, H. Y., Han, K. H., Park, H., & Park, C. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0549-8 · Cited by 6
Comparison of Apolipoprotein (ApoB/ApoA-1) and Lipoprotein (Total Cholesterol/HDL) Ratios in Obese Adolescents
Alemzadeh, R., & Kichler, J. (2017) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0135 · Cited by 6
Cardiovascular Disease Risk Across a Spectrum of Adverse Plasma Lipid Combinations by Gender and Glycemic Status
Liu, X., Yang, Y., Kang, F., Li, J., Zhou, M., Ma, X., Yu, T., Zhang, T., & Xue, F. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.058 · Cited by 5
Advances in Lipid Testing and Management in Patients with Diabetes Mellitus
Vasudevan, M. M., & Ballantyne, C. M. (2009) · Endocrine Practice · doi:10.4158/ep09190.ra · Cited by 5
Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy
Weart, C. W., & Hogan, R. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.516747 · Cited by 5
Potential effects on clinical management of treatment algorithms on the basis of apolipoprotein-B/A-1 and total/high-density lipoprotein-cholesterol ratios
Vodnala, D., Bard, R. L., Krishnan, S. M., Jackson, E. A., Rubenfire, M., & Brook, R. D. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.02.004 · Cited by 5
Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients
Farnier, M., Taggart, W. V., Dong, Q., Lin, J., Shah, A. K., & Brudi, P. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.02.009 · Cited by 5
Role of Non High Density Lipoprotein Cholesterol (Non HDL-C) in Predicting Coronary Artery Disease
Kumar, V. B., Guntakalla, Y. R., Thomas, Z., Rajasekaran, U. R., & Gnanasekaran, P. (2015) · Indian Journal of Pharmacy Practice · Cited by 5
Non‐HDL cholesterol is an independent predictor of long‐term cardiovascular events in patients with dyslipidemia after renal transplantation
Karabulut, U., & Çakır, Ü. (2021) · International journal of clinical practice · doi:10.1111/ijcp.14465 · Cited by 5
Serum apolipoprotein E levels predict residual cardiovascular risk in patients with chronic coronary syndrome undergoing first percutaneous coronary intervention and on-statin treatment
Fukase, T., Dohi, T., Chikata, Y., Takahashi, N., Endo, H., Doi, S., Nishiyama, H., Kato, Y., Okai, I., Iwata, H., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.021 · Cited by 5
Comparison of the various lipid ratios and indices for risk assessment in patients of myocardial infarction
Goswami, B., Rajappa, M., Chakraborty, B., Patra, S. K., Kumar, S., & Mallika, V. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.01.019 · Cited by 5
A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment
Bays, H. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.013 · Cited by 5
Anti-hyperlipidemic effect of Vitex doniana in poloxamer induced hyperlipidemia
Sheneni, V. D., Odiba, V. A., Omede, A., & Idih, F. M. (2018) · MOJ Biology and Medicine · doi:10.15406/mojbm.2018.03.00093 · Cited by 5
LDL-C or apoB as the best target for reducingcoronary heart disease: should apoB be implemented into clinical practice?
Vaverková, H. (2011) · Clinical Lipidology · doi:10.2217/clp.10.75 · Cited by 5
High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 1: a review basis for updating guidelines
Walldius, G. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2543537 · Cited by 4
Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease
Boronat, M., García-Cantón, C., López-Ríos, L., Quevedo, V., Lorenzo-Villegas, D. L., Batista, F., Riaño, M., & Novoa, F. J. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113511834 · Cited by 4
Plasma Amino Acids and Residual Hypertriglyceridemia in Diabetic Patients Under Statins: Two Independent Cross-Sectional Hospital-Based Cohorts
Wang, S., Cao, Y., Sun, X., Hong, M., Fang, Z., Luo, H., Sun, H., & Yang, P. C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.605716 · Cited by 4
Exploring Canine Mammary Cancer through Liquid Biopsy: Proteomic Profiling of Small Extracellular Vesicles
Novais, A. A., Tamarindo, G. H., Melo, L. M. M., Balieiro, B. C., Nobrega, D., dos Santos, G., Saldanha, S. F., de Souza, F. F., Chuffa, L. G. D. A., Bracha, S., et al. (2024) · Cancers · doi:10.3390/cancers16142562 · Cited by 4
Dual PPARα/γAgonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
Samuelsson, O. G., Attman, P.-O., Gause‐Nilsson, I. A. M., Svensson, M. K. E., & Alaupovic, P. (2013) · PPAR Research · doi:10.1155/2013/391628 · Cited by 4
Relationship between plasma apolipoprotein B concentrations and LDL particle number
Pourfarzib, R., Morris, P. B., McLain, K. H., Malave, H. A., Underberg, J. A., Le, N., Shapiro, M., & Winegar, D. A. (2014) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s65976 · Cited by 4
EFFECT OF THE EARLY INTENSIVE MULTIFACTORIAL THERAPY ON THE CARDIOVASCULAR RISK IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES: AN OBSERVATIONAL, PROSPECTIVE STUDY
Ştefan, R., Niţă, C., Craciun, A. E., Rusu, A., & Hâncu, N. (2015) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-406 · Cited by 4
Effectiveness of methotrexate therapy with occasional corticosteroid in rheumatoid arthritis
Patel, S. L., Kumar, V., Mishra, R., Chandra, V., Negi, M. P. S., Tripathy, B. C., Prakash, J., & Gupta, V. (2015) · Current Orthopaedic Practice · doi:10.1097/bco.0000000000000213 · Cited by 4
LDL particle size and antioxidant HDL function improve after sustained virological response in patients with chronic HCV
Vargas, J. I., Rivera, K., Arrese, M. A., Benítez, C., Francisco Barrera, M., Monrroy, H., Arab, J. P., Pino, K., Barrera, A., López‐Lastra, M., et al. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100555 · Cited by 4
Combined associations of cardiorespiratory fitness and grip strength with non-high-density lipoprotein cholesterol concentrations among Japanese children and adolescents
Kidokoro, T., & Miyashita, M. (2020) · The Journal of Physical Fitness and Sports Medicine · doi:10.7600/jpfsm.9.135 · Cited by 4
Clinical Strategies for Managing Dyslipidemias
Bronas, U. G., & Salisbury, D. L. (2013) · American Journal of Lifestyle Medicine · doi:10.1177/1559827613507534 · Cited by 5
A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals
Bays, H. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.006 · Cited by 4
Comparison of Therapeutic Lipid Target Achievements Among High-Risk Patients in Oman
Al-Waili, K., Al-Zakwani, I. S., Al‐Dughaishi, T., Baneerje, Y., Al-Sabti, H. A., Al-Hashmi, K., Farhan, H., Habsi, K. A., Al-Hinai, A. T., & Al‐Rasadi, K. (2013) · Angiology · doi:10.1177/0003319713482572 · Cited by 4
Utility of Advanced Lipoprotein Testing in Clinical Practice
Feingold, K. R., & Grünfeld, C. (2016) · Europe PMC (PubMed Central) · Cited by 4
The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model
(2010) · Clinical Governance An International Journal · doi:10.1108/cgij.2010.24815cae.003 · Cited by 4
Which lipid fraction is the target and how often should this be monitored?
Thompson, G. R. (2010) · Heart · doi:10.1136/hrt.2009.177394 · Cited by 4
SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study
Yang, H., Ning, Y., Chen, M., & Jia, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241309674 · Cited by 3
Total cholesterol/high-density lipoprotein cholesterol-related indices as predictors of obstructive sleep apnea and cardiovascular mortality: A cross-sectional study
Gu, Y., Xu, J., & Hu, X. G. (2025) · Medicine · doi:10.1097/md.0000000000042872 · Cited by 3
High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 2: a review basis for updating guidelines
Walldius, G. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2543535 · Cited by 3
Lipid profile of the ethanol - methanol (1:1) extracts of Anacadium occidentale and Jatropha tanjorensis administration in Wistar rats
Usin, S. G., Dimeji, I. Y., Okon, U. E., & Daramola, O. O. (2022) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2022.18.3.0030 · Cited by 3
Mini-Review: Immunogenic epitopes in apolipoprotein B-100 for atheroprotective immunization
Gerdes, N., & Klingenberg, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1448664 · Cited by 3
Carotid Ultrasound, Coronary Calcium, and Dyslipidemia Patterns in the MESA (Multi-Ethnic Study of Atherosclerosis) Cohort
Mancini, G. B. J., & Frohlich, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.084 · Cited by 2
Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study
Straczek, C., Tafflet, M., Barberger‐Gateau, P., Bertrand, M., Dupuy, A., Ducimetière, P., & Empana, J. P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.040 · Cited by 3
Clinical Manifestations of Atherosclerosis
Klingenberg, R., Hasun, M., Corti, R., & Lüscher, T. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0338-8_3 · Cited by 3
Upregulation of TNF-α by Triglycerides is Mediated by MEK1 Activation in Jurkat T Cells
Lim, J., Yang, E. J., & Chang, J. H. (2018) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2018.24.3.213 · Cited by 3
Insights into gene expression responses to infections in teleosts using microarray data: a systematic review
Caruffo, M., Mandaković, D., Cabrera, P., Pacheco, I., Montt, L., Chávez‐Báez, I., Mejías, M., Vera‐Tamargo, F., Pérez-Valenzuela, J., Carrasco‐Labra, A., et al. (2020) · Reviews in Aquaculture · doi:10.1111/raq.12462 · Cited by 3
Trends in TC/HDL and LDL/HDL Ratios across the Age Span: Data from the 2007-2018 National Health and Nutrition Examination Survey (NHANES)
Wang, I., Kapellusch, J. M., Hou, S., Rahman, M. H. U., Li, X., & Ritchie, D. (2021) · Asian Journal of Complementary and Alternative Medicine · doi:10.53043/2347-3894.acam90002 · Cited by 3
The relevance of remnant cholesterol as a guide for lipid management in Indian subjects undergoing coronary revascularization
Bansal, M., Kasliwal, R. R., Chandra, P., Kapoor, R., Chouhan, N., Bhan, A., & Trehan, N. K. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103183 · Cited by 3
Can Apolipoproteins apoB and apoB/apoA1 Ratio Predict Future Cardiovascular Risk Post Acute Coronary Syndrome? A Retrospective Cohort Study
Desplantie, O., & Ramanathan, K. (2016) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000443 · Cited by 3
Waist-to-height ratio as a clinical predictor for cardiovascular risks and insulin resistance in children and adolescents with exogenous obesity
Soliman, H. M. A. L., Ahmed, S., & Ibrahim, A. (2021) · Egyptian Pediatric Association Gazette · doi:10.1186/s43054-021-00085-9 · Cited by 3
Cholesterol
Pokharel, Y., Negi, S., & Virani, S. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00008-6 · Cited by 3
A high-carbohydrate diet effects on the A allele of hepatic lipase polymorphism on the apoB100/apoAI ratio in young Chinese males.
Hu, M., Li, Z., & Fang, D. Z. (2012) · PubMed · Cited by 3
Optimal lipid targets for the new era of cardiovascular prevention
Ramjee, V., Eapen, D. J., & Sperling, L. S. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06478.x · Cited by 3
Quel bilan lipidique et comment l’interpréter chez le patient ayant une maladie coronaire ?
Farnier, M. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2009.03.004 · Cited by 3
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease
Vaverková, H., Farnier, M., Averna, M. R., Missault, L. H., Viigimaa, M., Dong, Q., Shah, A. K., Johnson‐Levonas, A. O., & Brudi, P. (2011) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2011.02.008 · Cited by 3
Correlation of VEGF genetic polymorphisms and lipid profile to aortic calcification
Yadav, B. K., Hong, Y., & Shin, B. (2014) · Gene · doi:10.1016/j.gene.2014.08.010 · Cited by 3
LDL reduction: How low should we go and is it safe?
Robinson, J. G. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0076-3 · Cited by 3
Pravastatin and fenofibrate in combination (Pravafenix®) for the treatment of high-risk patients with mixed hyperlipidemia
Farnier, M. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.37 · Cited by 3
Leucocyte‐bound apolipoprotein B in the circulation is inversely associated with the presence of clinical and subclinical atherosclerosis
de Vries, M. A., Klop, B., van der Meulen, N., van de Geijn, G. M., Prinzen, L., van der Zwan, E., Birnie, E., Tervaert, J. W. C., Liem, A. H., de Herder, W. W., et al. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12650 · Cited by 3
Role of inflammation versus hypercholesterolemia in the development of atherosclerosis in male albino rats
Gomaa, R., Ibrahim, S., Ismail, S., & Ibrahim, H. G. (2018) · Al-Azhar Assiut Medical Journal · doi:10.4103/azmj.azmj_54_18 · Cited by 3
Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk
Nordestgaard, B. G., & Varbo, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_8 · Cited by 3
Differences in lipid parameters among statins treated patients with coronary arteriosclerosis – a pilot study
Burchardt, P., Żurawski, J., Kubacki, T., Żuchowski, B., & Wysocki, H. (2012) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201100260 · Cited by 2
Lipoprotein Particles as Shuttles for Hydrophilic Cargo
Weber, F., Axmann, M., Hörner, A., Schwarzinger, B., Weghuber, J., & Plochberger, B. (2023) · Membranes · doi:10.3390/membranes13050471 · Cited by 2
Apolipoprotein L3 inhibits breast cancer proliferation and modulates cell cycle via the P53 pathway
Yu, H., Li, S., Li, X., Liu, Y., Wang, Z., Cui, M., Jin, F., & Yu, X. (2024) · Journal of Cancer · doi:10.7150/jca.96903 · Cited by 2
Non-high-density lipoprotein cholesterol outperforms low-density lipoprotein cholesterol in predicting cardiovascular events among high-risk Asians
Manosroi, W., Phinyo, P., Phimphilai, M., Hutayanon, P., Gunaparn, S., Phrommintikul, A., & Wongcharoen, W. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.01.002 · Cited by 2
Using Apolipoprotein B to Manage Dyslipidemia–Reply–I
Jacobson, T. A., & Harper, C. R. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0378 · Cited by 2
Laboratory validation of a low density lipoprotein apolipoprotein-B assay
Kelsey, D. E., Toher, J. L., Foster, M. T., Boulanger, J. A., & Cervinski, M. A. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.07.016 · Cited by 2
An alternative marker of low-density lipoprotein cholesterol in coronaryartery disease: non-high-density lipoprotein cholesterol
Ercan, M., Oğuz, E. F., Yılmaz, F. M., Boğdaycıoğlu, N., Ünal, K., Şahin, D., & Uysal, S. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1308-116 · Cited by 2
Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk Outcome
Al‐Rasadi, K., & Al-Sabti, H. A. (2015) · Oman Medical Journal · doi:10.5001/omj.2015.81 · Cited by 2
Changes in Serum Markers of Atherogenesis and Hematological Profile after the consumption of Quail eggs
Ekpenyong, C. E., Patrick, E. S., & Akpan, K. S. (2017) · Archive of Food and Nutritional Science · doi:10.29328/journal.afns.1001001 · Cited by 2
Statin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk Markers
White, A. M. B., Mishcon, H. R., Redwanski, J. L., & Hills, R. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113748 · Cited by 2
Serum apolipoproteins and mortality risk: evidence from observational and Mendelian randomization analyses
Li, J., Ge, X., Liu, X., Fu, C., Miao, J., Zhao, W., Miao, L., & Hang, D. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.002 · Cited by 2
Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?
Steiner, G. A. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283189c2b · Cited by 2
Lipid Parameters and Cardiovascular Events in Patients Taking Statins
Brook, R. D., & Rubenfire, M. (2012) · JAMA · doi:10.1001/jama.2012.6616 · Cited by 2
Modification of Lipid Profile, LDL Subfractions and other Cardiovascular Risk Markers in Hypercholesterolemic Women through the Sea Buckthorn Juice ConsumptionPreprint
Kopčeková, J., Mrázová, J., Fatrcová-Šramková, K., Chlebo, P., Bihari, M., Gažarová, M., Lenártová, P., Habánová, M., & Navrátilová, A. (2023) · Preprints.org · doi:10.20944/preprints202309.1474.v1 · Cited by 2
Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
The place of non-high-density lipoprotein cholesterol and triglycerides in the assessment of cardiovascular risk: Resolution of the Panel of Experts
Boytsov, S. A., Вавилова, Т. В., Gurevich, V. S., Drapkina, O. M., Drozdova, L. Y., Владиславович, Е. М., Звартау, Н. Э., & Сергиенко, И. В. (2025) · Russian Journal of Preventive Medicine · doi:10.17116/profmed2025280417 · Cited by 1
Exploring the evolving role of apolipoproteins in oncology: global trends and emerging frontiers
Tian, D., Hu, Z., Yang, Z., Zhao, L., Zhao, H., Sang, X., Du, S., Luo, Y., Zhang, L., Xu, Y., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06360-1 · Cited by 1
Association Between Ratio of Cholesterols and Coronary Artery Stenosis According to Low-Density Lipoprotein-Cholesterol Levels and Statin Use
Kim, S. R., Kim, M., Kim, H., Cho, D. H., Kim, H.-L., Kim, Y., Na, J. O., Yoon, H., Shin, M. S., Kim, M., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2025.0262 · Cited by 1
Advanced Lipid Testing
Sorrentino, M. J. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-502-6_5 · Cited by 1
Determination of PON1 Gene Polymorphisms in Iranian Individuals with High LDL/HDL Ratios
Khoshi, A., Mortazavi, Y., Sokhanvar, S., Tanzifi, A., Akbari, A., Kalantari, S., & Mazloomzadeh, S. (2015) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-015-0479-z · Cited by 1

Authors: Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., Szarek, M., LaRosa, J. C., Pedersen, T. R., & Grundy, S. M.
Affiliations: State University of New York (US)
From the Academic Medical Center, University of Amsterdam (J.J.P.K., W.A.v.d.S., S.M.B.), Amsterdam, the Netherlands; Center for Preventive Medicine, Ullevål University Hospital (I.H., T.R.P.), Oslo, Norway; Pfizer Inc (M.G., N.B.C., D.A.D., M.S.), New York, NY; the Heart Research Institute (P.B.), Sydney, Australia; Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine (P.D.), San Francisco, Calif; University Hospital (A.G.O.),...
ORCID: Kastelein, John J.P.
Gaffney, Michael
Cater, Nilo B.
Deedwania, Prakash
Olsson, Anders G.
Boekholdt, S. Matthijs
Demicco, David A.
Szarek, Michael
Pedersen, Terje R.
Grundy, Scott M.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2008-06-10
Volume: 117
Issue: 23
Pages: 3002-3009
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.107.713438
OpenAlex: W1982036768
Cited by: 478
References: 45
Citations by year: 2026: 10 · 2025: 14 · 2024: 16 · 2023: 17 · 2022: 16 · 2021: 24 · 2020: 23 · 2019: 24 · 2018: 23 · 2017: 25 · 2016: 14 · 2015: 32 · 2014: 23 · 2013: 36 · 2012: 31
FWCI: 52.34
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: statin therapy, non-HDL cholesterol, apolipoprotein B, apolipoprotein B/A-I ratio, TC/HDL-C ratio, LDL cholesterol, apolipoprotein A-I, cardiovascular events, coronary artery disease, lipid-lowering targets, lipoprotein ratios
MeSH terms: Aged, Apolipoproteins B, Coronary Disease, Female, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk, Triglycerides, Proportional Hazards Models, Randomized Controlled Trials as Topic, Databases, Factual, Apolipoprotein A-I, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks